Khiron Receives Approval To Renew Its Normal Course Issuer Bid

Rhea-AI Summary

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQB: KHRNF) announced on September 13, 2021, that it has received approval from the TSX Venture Exchange to renew its Normal Course Issuer Bid (NCIB) for repurchasing up to 8,955,853 common shares, representing approximately 5% of outstanding shares. The repurchases will start on September 14, 2021, and will continue until one year from that date or until the maximum number of shares is acquired. The previous NCIB resulted in the purchase of 511,500 shares at an average price of $0.41 each.

Positive

• Approval to renew NCIB supports shareholder value by enabling share repurchases.
• Repurchase of up to 8,955,853 shares represents a strategic move to enhance stock value.

Negative

• None.

TORONTO, Sept. 13, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce that, further to its September 9, 2021 press release, the Company has received final approval from the TSX Venture Exchange (the "TSXV") to renew its normal course issuer bid to repurchase, for cancellation, up to 8,955,853 common shares of the Company ("Shares"), representing approximately 5% of the Company's presently issued and outstanding Shares (the "NCIB").

Purchases under the NCIB will commence on or about September 14, 2021 and will expire on the earlier of: (i) one year from such commencement; or (ii) the date on which the Company has purchased the maximum number of Shares to be acquired under the NCIB. The NCIB will be conducted on behalf of the Company by Scotia Capital Inc. (the "Broker"). The purchase and payment for the Shares will be made in accordance with TSXV requirements at the market price of the applicable securities at the time of acquisition, plus brokerage fees, if any, charged by the Broker. The actual number of Shares that may be purchased and the timing of any such purchases will be determined at management's discretion and will be made in accordance with the requirements of the TSXV.

The Company's prior normal course issuer bid for the purchase of up to 5,830,615 Shares expired on March 3, 2021. Under this bid, the Company purchased for cancellation 511,500 of its outstanding Shares through the facilities of the TSXV, representing approximately 0.4% of its issued and outstanding Shares at the time of commencement of the bid, at a weighted average price of $0.41 per Share for a total cost of $212,389.

A copy of the Company's Notice of Intention to commence the NCIB filed with the TSXV may be obtained, by any shareholder without charge, by contacting the Company's Chief Financial Officer, Joel Friedman.

About Khiron Life Sciences Corp.

Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. In particular, this press release includes forward-looking information relating to Khiron's intention to purchase Shares pursuant to the normal course issuer bid, the number of Shares to be purchased, the timing of such purchases and the impact of such purchases on the value of the remaining Shares. Actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. There is no assurance that any of the events or expectations will occur or be realized. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statements have been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Further information in respect of the Company can be found at www.khiron.ca.

View original content to download multimedia:https://www.prnewswire.com/news-releases/khiron-receives-approval-to-renew-its-normal-course-issuer-bid-301375669.html

SOURCE Khiron Life Sciences Corp.

FAQ

When does Khiron's new Normal Course Issuer Bid begin?

Khiron's new Normal Course Issuer Bid will commence on September 14, 2021.

How many shares can Khiron repurchase under its NCIB?

Khiron can repurchase up to 8,955,853 common shares, approximately 5% of its outstanding shares.

What was the outcome of Khiron's previous NCIB?

Under the previous NCIB, Khiron purchased 511,500 shares at an average price of $0.41, totaling $212,389.

What is the purpose of Khiron's NCIB?

The purpose of Khiron's NCIB is to enhance shareholder value by repurchasing shares.

What is the maximum duration of Khiron's NCIB?

The NCIB will last until the earlier of one year from commencement or until the maximum number of shares is purchased.